What Factors Affect a Sufficient Lansoprazole Dose?
Lansoprazole (lansoprazole), also known as daclopron and lansoprazole, is a white crystalline powder chemical. Chemical name 2-[[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridyl] methyl] -sulfinyl] -1 H -benzimidazole, molecular formula It is C 16 H 14 F 3 N 3 O 2 S, and the molecular weight is 369.36100.
- Chinese name
- Lansoprazole tablets
- Foreign name
- Lansoprazole Tablets
- CAS number
- 103577-45-3
- Molecular formula
- C16H14F3N3O2S
- Molecular weight
- 369.36100
- Lansoprazole (lansoprazole), also known as daclopron and lansoprazole, is a white crystalline powder chemical. Chemical name 2-[[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridyl] methyl] -sulfinyl] -1 H -benzimidazole, molecular formula It is C 16 H 14 F 3 N 3 O 2 S, and the molecular weight is 369.36100.
Lansoprazole Tablets Compound Introduction
Lansoprazole Tablets Basic Information
- Chinese name: Lansoprazole
- Chinese alias: Dacpron; Langsonazol;
- English name: lansoprazole
- English alias: Lanz; OGAST; Lancid; LANZOR; Promp;
- CAS number: 103577-45-3
- Molecular formula: C 16 H 14 F 3 N 3 O 2 S
- Molecular weight: 369.36100
- Exact mass: 369.07600
- PSA: 87.08000
- LogP: 4.38090 [1]
Lansoprazole tablets physical and chemical properties
- Appearance and properties: white crystalline powder
- Density: 1.5 g / cm 3
- Melting point: 178-182 ° C dec.
- Boiling point: 555.8ºC at 760 mmHg
- Flash point: 289.9ºC
- Refractive index: 1.591
- Storage conditions: 2-8ºC
- Vapor pressure: 2.55E-10mmHg at 25 ° C [1]
Overview of basic information about lansoprazole tablets
Lansoprazole Tablets Ingredients
- The main ingredients of this product are: Lansoprazole.
Chemical name: 2-[[[3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridyl] methyl] -sulfinyl] -1H-benzimidazole.
Chemical Structure:
Molecular formula: C 16 H 14 F 3 N 3 O 2 S
Molecular weight: 369.37
Lansoprazole Tablet Properties
- This product is an enteric-coated tablet that appears white or pale yellow-brown after removal of the coating [2] .
Lansoprazole tablets indications
- Gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome (gastrinoma) [2] .
Lansoprazole Tablet Specifications
- 15mg
Lansoprazole tablets dosage
- Oral, not chewable, usually adults take lansoprazole tablets once a day, 1 to 2 tablets (15-30mg). Duodenal ulcer needs to be taken continuously for 4-6 weeks; gastric ulcer reflux esophagitis and Zhuo-Ai syndrome need to be taken continuously for 6-8 weeks; or as directed by a doctor [2] .
Lansoprazole tablets adverse reactions
- 1. Allergic reactions: Occasionally rash, itching and other symptoms, please stop taking medicine when the above symptoms occur.
2. Blood system: occasional anemia, leukocytosis, eosinophilia and other symptoms, thrombocytopenia rarely occur. 3. Digestive system: occasional constipation, diarrhea, thirst, abdominal distension and other symptoms. Occasionally, GOT, GPT, ALP, LDH, and -GTP rise, so you must observe carefully, and if there is an abnormal phenomenon, you should take appropriate measures such as withdrawal.
4. Psychological and nervous system: Occasionally headache, drowsiness and other symptoms. Insomnia, dizziness and other symptoms rarely occur.
5. Urogenital system: Frequent urination, proteinuria, and male fistula can occur.
6. Others: Occasionally fever, elevated total cholesterol, and elevated uric acid. [2]
Lansoprazole taboo
- Those who are allergic to this product are prohibited.
Lansoprazole tablets precautions
- (1) Pay attention to observation during treatment. Due to lack of long-term experience, it is not recommended for maintenance treatment.
(2) When taking this product, please do not chew it, swallow the whole tablet with water.
(3) People with liver dysfunction and elderly people should be used with caution.
(4) The symptoms of gastric cancer may be masked by using this product, so it can be administered on the basis of excluding the possibility of gastric cancer [2] .
Lansoprazole tablets for pregnant and lactating women
- 1. It has been reported that in animal experiments, the plasma concentration of the drug in the fetus is higher than the plasma concentration of the mother, so for pregnant women or women with the possibility of pregnancy, it can only be used in cases where the benefit of treatment is judged to exceed the risk.
2. Animal experiments show that lansoprazole will be distributed in breast milk. Therefore, it is best to avoid medication in breast-feeding women and avoid breast-feeding when it must be applied. [2]
Lansoprazole tablets for children
- The safety of pediatric use has not been established (clinical experience in children is rare) [2] .
Lansoprazole tablets for elderly
- Generally speaking, the gastric acid secretion capacity and other physiological functions of elderly patients will be reduced, please pay attention to observation during medication [2] .
Lansoprazole tablets drug interactions
- Lansoprazole can delay the metabolism and excretion of diazepam and phenytoin, increase the peak plasma concentration of acetaminophen, and shorten the peak time [2] .
Lansoprazole tablets overdose
- This test was not performed and there is no reference [2] .
Lansoprazole Tablets Pharmacology and Toxicology
- Pharmacological effects:
This product is a benzimidazole compound, which is transferred to the gastric mucosa after oral absorption, and is converted into an active metabolite under acidic conditions. The activator specifically inhibits the gastric wall cell H + / K + -ATPase system and blocks gastric acid secretion. Last step. This product inhibits basal gastric acid secretion and stimulates gastric acid secretion in a dose-dependent manner. This product has no antagonistic effect on choline and histamine H 2 receptors.
Toxicology research:
Genotoxicity: Ames test, rat liver cell extraprogrammed DNA synthesis test, mouse micronucleus test, rat bone marrow cell chromosome aberration test results were all negative. In vitro human lymphocyte chromosome aberration test results were positive.
Reproductive toxicity: oral administration of this product at 150 mg / kg / day (based on body surface area equivalent to 40 times the human dose) has no effect on reproductive capacity and reproductive behavior in rats. Teratogenicity studies have shown that pregnant rats take 150 mg / kg / day of this product orally, and pregnant rabbits take 30 mg / kg / day of this product (based on body surface area, which is equivalent to 16 times the human dose). This product and its metabolites can be secreted from rat milk.
Carcinogenicity study: SD rats orally take 5 to 150 mg / kg / day of this product for 24 consecutive months, and the results show that this product induces gastrointestinal chromaffin-like (ECL) cell proliferation and benign ECL cell tumor in a dose-dependent manner: stomach of test animals Increased frequency of intestinal metaplasia. The incidence of testicular mesenchymal adenoma in male rats increased in a dose manner. CD-1 mice were orally administered 15 to 600 mg / kg / day for 24 consecutive months (equivalent to 2 to 80 times the human dose in terms of body surface area). As a result, the product induced ECL cell proliferation in a dose-dependent manner. The incidence of liver tumors in drug-bearing mice increased. The incidence of tumors in male mice of the 300 and 600 mg / kg / day group and female mice of the 150 and 600 mg / kg / day group exceeded the range of historical tumor incidence in this strain of mice. Testicular reticuloadenoma occurred in mice given this product at 75 ~ 600mg / kg / day [2] .
Lansoprazole tablets pharmacokinetics
- The bioavailability of lansoprazole has individual differences. Healthy adults take 30 mg orally on a fasting basis, Tmax is 1.5 ~ 2.2h, Cmax is 0.75 ~ 1.15mg / l, and T 1/2 is 1.3 ~ 1.7h. Lansoprazole is metabolized into active metabolites in the liver. It is mainly excreted through bile and urine. No prototype drug can be detected in urine. All metabolites are metabolites. Until 24 hours after taking, its excretion rate in urine is 13.1 ~ 14.3%. Lansoprazole has no accumulation in the body [2] .
Lansoprazole Tablets Storage
- Shaded and sealed (10 30 ) [2] .
Lansoprazole Tablets Packaging
- Packaging of medicinal aluminum-plastic composite film, 7 pieces / board / box; 10 pieces / board / box; 12 pieces / board / box; 14 pieces / board / box; 18 pieces / board / box; 10 pieces / board * 2 board / Box; 14 pieces / board * 2board / box [2] ;
Lansoprazole tablets expiration date
- 36 months
Lansoprazole tablet implementation standard
- Chinese National Pharmacopoeia 2010 Edition Two National Drug Standards WS 1- (X-148) -2003Z